A hormone linked to the human sleep cycle has been identified as a new weapon against Alzheimer’s disease.
A new study has shown that a combination of exercise and a daily intake of melatonin, the natural hormone which causes drowsiness at night, had a positive effect on rodents suffering from the illness.
In the first study of its kind, researchers at Korea’s leading university and the RNL Bio Stem Cell Technology Institute announced this week the results of a study that suggests an astounding possibility: adult stem cells may not only have a positive effect on those suffering from Alzheimer’s disease, they can prevent the disease. Using fat-derived adult stem cells from humans [scientific term: adMSCs, or human, adipose-derived mesenchymal stem cells], researchers were able to cause Alzheimer’s disease brains in animal models to regenerate. The researchers, for the first time in history, used stem cells to identify the mechanism that is key to treatment of Alzheimer’s disease, and demonstrated how to achieve efficacy as well as prevention of the symptoms of Alzheimer’s with adult stem cells, a “holy grail” of biomedical scientists for decades.
I believe there are two times in life when it is never more apparent we are guided by a higher power: birth and death.
I felt this potent force through the miracle of birth when I brought my daughter, Jazlyn, into the world 18 years ago. And I sensed that same ethereal presence when my beloved mother, Rose Beebe, peacefully left the material plane on Sept. 8 after a courageous battle with Alzheimer’s.
People with diabetes have a higher risk of dementia. But could dementia actually be a type of diabetes?
Some researchers say yes. The disease that affects millions of Americans — Alzheimer’s — is actually “type 3” diabetes, not a separate condition, some say.
Alzheimer’s is a devastating disease: Victims lose their memories, personalities, sense of time, and grip on reality as friends and families watch their loved ones slowly lose their identities, and eventually their lives.
The disease afflicts an estimated 5.4 million people in the U.S., where the memory-robbing illness is the 6th-leading killer of Americans, according to Alzheimer’s Association. The association estimates that more than $200 billion will be spent between drugmakers and patients for research, medication and caregivers this year.